Completed PHASE2 INTERVENTIONAL 2-arm NCT01066715

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

Sponsor: XOMA (US) LLC

Conditions Type 2 Diabetes Mellitus

Interventions Placebo XOMA 052

Updated 7 times since 2017 Last updated: Sep 30, 2011 Started: Jan 31, 2010 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01066715, this PHASE2 trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by XOMA (US) LLC, it has been updated 7 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

XOMA (US) LLC

Data source: XOMA (US) LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arlington, United States , Arlington Heights, United States , Atlanta, United States , Austin, United States , Bradenton, United States , Brooksville, United States , Burke, United States , Butte, United States , Chandler, United States , Charlotte, United States and 57 more locations